{"title":"胸椎血管内主动脉修复术患者的中长期疗效","authors":"Yaşar Gökkurt","doi":"10.5606/e-cvsi.2021.1141","DOIUrl":null,"url":null,"abstract":"Objectives: In this study, we aimed to examine the midand long-term results of the patients undergoing thoracic endovascular aortic repair (TEVAR) in our clinic. Patients and methods: Between June 2006 and October 2018, a total of 71 patients (59 males, 12 females; mean age: 60.9±13.3 years; range, 17 to 79 years) who underwent TEVAR electively or urgently were retrospectively analyzed. Data including demographic and clinical characteristics of the patients and operative data were recorded. Results: Of the patients, 22 (31%) were urgently operated and 49 (69%) were electively operated. Cerebrovascular disease (CVD) developed in three (4.2%) patients. Thirty-day overall survival of patients who were operated on emergency was found to be 72.7%, and this rate was 98% in elective patients (p=0.001). One-year overall survival of our patient series was 76.1%. One-year survival rate of emergency patients was 54.5%, and this rate was 85.7% in elective patients (p=0.002). Two-year overall survival of emergency patients was 45.5% and it was 79.6% in elective patients (p=0.002). While the survival rate of preoperative smokers after two years was 60.8%, it was calculated as 90% of preoperatively non-smokers (p=0.022). Conclusion: Thoracic endovascular aortic repair treatment seems to show similar results to open surgery in terms of mortality and other complications in the midand long-term. With the developing stent-graft technology, TEVAR results can be even better in the future.","PeriodicalId":229686,"journal":{"name":"Cardiovascular Surgery and Interventions","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Mid- and long-term results in patients with thoracic endovascular aortic repair\",\"authors\":\"Yaşar Gökkurt\",\"doi\":\"10.5606/e-cvsi.2021.1141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: In this study, we aimed to examine the midand long-term results of the patients undergoing thoracic endovascular aortic repair (TEVAR) in our clinic. Patients and methods: Between June 2006 and October 2018, a total of 71 patients (59 males, 12 females; mean age: 60.9±13.3 years; range, 17 to 79 years) who underwent TEVAR electively or urgently were retrospectively analyzed. Data including demographic and clinical characteristics of the patients and operative data were recorded. Results: Of the patients, 22 (31%) were urgently operated and 49 (69%) were electively operated. Cerebrovascular disease (CVD) developed in three (4.2%) patients. Thirty-day overall survival of patients who were operated on emergency was found to be 72.7%, and this rate was 98% in elective patients (p=0.001). One-year overall survival of our patient series was 76.1%. One-year survival rate of emergency patients was 54.5%, and this rate was 85.7% in elective patients (p=0.002). Two-year overall survival of emergency patients was 45.5% and it was 79.6% in elective patients (p=0.002). While the survival rate of preoperative smokers after two years was 60.8%, it was calculated as 90% of preoperatively non-smokers (p=0.022). Conclusion: Thoracic endovascular aortic repair treatment seems to show similar results to open surgery in terms of mortality and other complications in the midand long-term. With the developing stent-graft technology, TEVAR results can be even better in the future.\",\"PeriodicalId\":229686,\"journal\":{\"name\":\"Cardiovascular Surgery and Interventions\",\"volume\":\"7 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-08-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Surgery and Interventions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5606/e-cvsi.2021.1141\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Surgery and Interventions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5606/e-cvsi.2021.1141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mid- and long-term results in patients with thoracic endovascular aortic repair
Objectives: In this study, we aimed to examine the midand long-term results of the patients undergoing thoracic endovascular aortic repair (TEVAR) in our clinic. Patients and methods: Between June 2006 and October 2018, a total of 71 patients (59 males, 12 females; mean age: 60.9±13.3 years; range, 17 to 79 years) who underwent TEVAR electively or urgently were retrospectively analyzed. Data including demographic and clinical characteristics of the patients and operative data were recorded. Results: Of the patients, 22 (31%) were urgently operated and 49 (69%) were electively operated. Cerebrovascular disease (CVD) developed in three (4.2%) patients. Thirty-day overall survival of patients who were operated on emergency was found to be 72.7%, and this rate was 98% in elective patients (p=0.001). One-year overall survival of our patient series was 76.1%. One-year survival rate of emergency patients was 54.5%, and this rate was 85.7% in elective patients (p=0.002). Two-year overall survival of emergency patients was 45.5% and it was 79.6% in elective patients (p=0.002). While the survival rate of preoperative smokers after two years was 60.8%, it was calculated as 90% of preoperatively non-smokers (p=0.022). Conclusion: Thoracic endovascular aortic repair treatment seems to show similar results to open surgery in terms of mortality and other complications in the midand long-term. With the developing stent-graft technology, TEVAR results can be even better in the future.